As the results shown in Supplementary Table S2, the AUC for the predictors of combined testing of NLR, IL-6, and TyG is higher than FIB-4 in identifying participants with T2DM-NAFLD comorbidity from T2DM participants (Supplementary Table S2-2) and participants with T2DM from healthy people (Supplementary Table S2-3), further suggesting that the predictors may provide a better predictive capacity in screening patients with T2DM in the early stage or NAFLD in the T2DM patients. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.